Projects per year
Methods: We modelled HBV and HCV burden (including cirrhosis and liver cancer burden) and HIV at the country, regional, and global level. We extracted data on the proportion of notified HIV cases by transmission route and estimated the contribution of IDU to HBV and HCV disease burden using a cohort method that injecting drug use (IDU) to HBV and HCV disease burden using a cohort method that recalibrated individuals’ history of IDU, and accumulated risk of HBV and HCV due to IDU. We estimated data on current IDU from a meta-analysis of HBV and HCV incidence among injectors; and country-level data on the incidence of HBV and HCV between 1990 and 2013. We calculated estimates of burden of disease through three metrics: years of life lost (YLL), years of life lived with disability (YLD), deaths, and disability-adjusted life-years (DALYs).
Findings: In 2013, an estimated 10.08 million DALYs were attributable to previous exposure to HIV, HBV and HCV via IDU, a four-fold increase since 1990. In 2013, IDU was estimated to cause 4.0% (2.82 million DALYs (95% uncertainty interval (95%UI) 2.4-3.8 million DALYs), 1.1% (216,000; 101,000-338,000) and 39.1% (7.05 million; 5.88-8.15 million) of total DALYs due to HIV, HBV and HCV, respectively. IDU-attributable HCV burden was 2.5 times that for HIV. IDU-attributable HIV burden was highest in low- to middle-income countries, and IDU-attributable HCV burden highest in high-income countries.
Conclusions: IDU is a major contributor to GBD. There is a need to scale up efficacious interventions to prevent and treat these important causes of health burden.
- Bristol Medical School (PHS) - Professor in Public Health and Epidemiology - Deputy Head of School and Head of Population Health Sc
- Bristol Population Health Science Institute
- Health Protection Research Unit (HPRU)
- Centre for Academic Mental Health
- Infection and Immunity
- Centre for Academic Primary Care
Person: Academic , Member, Group lead